Filling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast Asia: insights from a real-world study in Thailand

Simple item page
dc.contributor.authorPrakit Anukoolwittaya
dc.contributor.authorAkarin Hiransuthikul
dc.contributor.authorThanakit Pongpitakmetha
dc.contributor.authorSekh Thanprasertsuk
dc.contributor.authorWanakorn Rattanawong
dc.date.accessioned2025-07-21T06:12:01Z
dc.date.issued2024-09-12
dc.description.abstractMost real-world data on CGRP mAbs have been published from high-income countries such as the USA, Western countries, Japan, Korea, and Singapore. However, data from low- and middle-income countries in Southeast Asia is lacking. This is the first real-world study from Thailand to describe the efficacy of CGRP mAbs therapy in migraine patients and to analyze the response trends between episodic migraine and chronic migraine.
dc.identifier.doi10.1186/s10194-024-01859-3
dc.identifier.urihttps://dspace.kmitl.ac.th/handle/123456789/13935
dc.subject.classificationMigraine and Headache Studies
dc.titleFilling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast Asia: insights from a real-world study in Thailand
dc.typeArticle

Files

Collections

All